SCHEMBL255285

SCHEMBL255285

COC(=O)C1CCC(C)CC1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
CHRNB2 P17787 2/20 0.43
CHRNA4 P43681 2/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA7 P36544 1/20 0.43
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
PPM1B O75688 1/20 0.41
PTPN1 P18031 1/20 0.41
PPP1CC P36873 1/20 0.41
BRD4 O60885 1/20 0.39
EPHX1 P07099 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL764832 1.00 TP53 (0.48) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL14424491 1.00 TP53 (0.48) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
Hydrochloric Acid SCHEMBL27278187 0.98 TP53 (0.47) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL12220653 0.93 TP53 (0.48) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL27025580 0.91 SMN1; SMN2 (0.49) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL2200767 0.89 TP53 (0.56) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL2948892 0.89 TP53 (0.56) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL74396 0.89 TP53 (0.56) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL244740 0.89
SCHEMBL30901182 0.89 SMN1; SMN2 (0.55) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119161372-A Bimetallic compound based on hydrazide pyrene skeleton, and preparation method and application thereof 万华化学集团股份有限公司 2024-12-20 CN claimed
CN-116410098-A Preparation method for synthesizing alpha-aminoketone compound from fatty aldehyde and secondary amine 西北工业大学 2023-07-11 CN claimed
US-20140030609-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND ENERGY STORAGE DEVICE USING SAME UBE INDUSTRIES, LTD. (JP) 2014-01-30 US claimed
US-4157435-A TITANIUM, ALUMINUM, SILOXANE COORDINATION CATALYST MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1979-06-05 US claimed
CN-122079745-A Efficient and energy-saving separation method for 1, 4-Cyclohexanedimethanol (CHDM) 2026-05-26 CN disclosed
EP-4192833-B1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES RICHTER GEDEON NYRT (HU) 2026-01-21 EP disclosed
US-12473293-B2 Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives RICHTER GEDEON NYRT. (HU) 2025-11-18 US disclosed
CN-114790480-B Primer probe and kit for detecting MMACHC gene mutation site 苏州淦江生物技术有限公司 2025-02-18 CN disclosed
CN-119161372-A Bimetallic compound based on hydrazide pyrene skeleton, and preparation method and application thereof 万华化学集团股份有限公司 2024-12-20 CN disclosed
CN-118206428-A Continuous preparation method and system of 1, 4-cyclohexanedimethanol and preparation method of Ni/Cu catalyst 上海戊正工程技术有限公司 2024-06-18 CN disclosed
EP-3490974-B1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) 2023-12-06 EP disclosed
US-20230295145-A1 PYRROLIDINE DERIVATIVES AND METHODS OF USE GENENTECH INC (US) 2023-09-21 US disclosed
CN-1223631-A Process for the preparation of cyclohexanedimethanol NEW JAPAN CHEM CO LTD (JP) 1999-07-21 CN disclosed
EP-0922690-A1 PROCESS FOR THE PREPARATION OF CYCLOHEXANEDIMETHANOL NEW JAPAN CHEMICAL CO.,LTD. (JP) 1999-06-16 EP disclosed
CN-1216522-A Therapeutic agent for diabetes JAPAN TOBACCO INC (JP) 1999-05-12 CN disclosed
EP-0885869-A1 THERAPEUTIC AGENT FOR DIABETES Japan Tobacco Inc. (JP) 1998-12-23 EP disclosed
CN-1099744-A Low pressure process for the manufacture of cyclohexanedicarboxylate esters EASTMAN CHEM CO (US) 1995-03-08 CN disclosed
US-4507290-A CONTRACEPTIVE WORLD HEALTH ORGANIZATION (CH) 1985-03-26 US disclosed
US-4157435-A TITANIUM, ALUMINUM, SILOXANE COORDINATION CATALYST MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1979-06-05 US disclosed
US-4085276-A CATALYST COMPOSED OF AN ORGANOMETALLIC COMPOUND AND THE REACTION PRODUCT OF A MAGNESIUM COMPOUND AND A TITANIUM COMPOUND MITSUI PETROCHEMICAL INDUSTRIES LTD. (JA) 1978-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295145-A1 PYRROLIDINE DERIVATIVES AND METHODS OF USE DPYD, TP53, GLS TP53 2/4885SMN1; SMN2 2183/4885CHRNB2 4708/4885
US-12473293-B2 Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives GABRA5, GABRA1, P2RX5 TP53 3362/4885SMN1; SMN2 2384/4885CHRNB2 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.